Literature DB >> 17430259

Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure.

Chabouk Anas1, Takenori Ozaki, Shoichi Maruyama, Tokunori Yamamoto, Momoka Zu Gotoh, Yoshinari Ono, Seiichi Matsuo.   

Abstract

OBJECTIVE: Renal ischemic reperfusion injury (IRI) is unavoidable and is still one of the major problems in renal transplantation. The aim of this study was to investigate the effects of olprinone, a phosphodiesterase III inhibitor, on renal IRI.
METHODS: After a right nephrectomy, renal IRI was induced in rats. Olprinone was given in two different ways: sustained systemic administration and transient local administration to the kidney. Control rats were treated with saline. Using a magnifying endoscope, the renal blood flow speed was measured at 23 h after reperfusion. Then, blood samples were collected, and kidney specimens were taken for histological study. In order to study the mechanism, we performed in vitro experiments, using human proximal renal tubular cells (HK-2) incubated with tumor necrosis factor (TNF)-alpha along with olprinone or saline, and interleukin (IL)-8 was measured in the culture supernatant.
RESULTS: In the saline group, the blood flow speed (BFS) was greatly reduced compared to that in normal kidneys. In both olprinone-treated groups, BFS of the renal microcirculation significantly increased, tubular damage and macrophage infiltration attenuated, and renal function greatly improved. Olprinone inhibited the increase in the IL-8 levels resulting from the incubation of HK-2 with TNF-alpha.
CONCLUSIONS: Our study successfully demonstrates that olprinone has renoprotective properties when applied locally as well as systemically. The results suggest that olprinone might be clinically useful in renal transplantation for the donor kidney, the recipient, and even in treating acute renal failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430259     DOI: 10.1111/j.1442-2042.2007.01689.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Epac-Rap signaling reduces cellular stress and ischemia-induced kidney failure.

Authors:  Geurt Stokman; Yu Qin; Hans-Gottfried Genieser; Frank Schwede; Emile de Heer; Johannes L Bos; Ingeborg M Bajema; Bob van de Water; Leo S Price
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

2.  Olprinone attenuates the development of ischemia/reperfusion injury of the gut.

Authors:  Concetta Crisafulli; Emanuela Mazzon; Maria Galuppo; Irene Paterniti; Rocco Caminiti; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2010-03-27       Impact factor: 17.440

3.  The effects of tadalafil on renal ischemia reperfusion injury: an experimental study.

Authors:  Feyzul Gasanov; Berna Aytac; Hakan Vuruskan
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

Review 4.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

5.  Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice.

Authors:  Emanuela Esposito; Emanuela Mazzon; Irene Paterniti; Daniela Impellizzeri; Placido Bramanti; Salvatore Cuzzocrea
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.